Resource Logo

A sero-epidemiological study on mother-to-child transmission of HTLV-I in southern Kyushu, Japan.


Asia Oceania J Obstet Gynaecol. 1992 Dec;18(4):371-7. Unique Identifier

In vertical transmission of HTLV-I the duration of breast-feeding seems to be an important risk factor. In this study, we made prospective and retrospective surveys on the rate of vertical transmission of HTLV-I in infants and their siblings born to HTLV-I seropositive mothers. The results obtained were as follows. (1) In the prospective study, 885 of the 16,283 pregnant women examined were HTLV-I seropositive, and the seropositive rate was 5.4%. The seroconversion rates of short-term (< 7 months) and long-term (> or = 7 months) breast-feeders were 3.8% (1/26 cases) and 25.0% (1/4 cases) respectively, and the rate of bottle-feeders was 5.6% (10/177 cases). Short-term breast-feeding tended to yield a lower seroconversion rate of infants. In addition, the seroconversion rate of short-term breast-feeders was nearly equal to that of bottle-feeders: 3.8% vs. 5.6%. (2) In the retrospective study, the seroconversion rates of short-term and long-term breast-feeders in their siblings were 4.5% (3/67 cases) and 14.0% (19/136 cases) respectively. There was a significant difference between the 2 groups (p < 0.01). Thus, the results of our retrospective and prospective studies suggest that short-term breast-feeding might lessen the risk of breast-milk-borne transmission of HTLV-I from carrier mothers to their children.

Adult *Breast Feeding Carrier State/EPIDEMIOLOGY/*IMMUNOLOGY Female Human HTLV-BLV Infections/PREVENTION & CONTROL/TRANSMISSION HTLV-I/*IMMUNOLOGY HTLV-I Antibodies/ANALYSIS Infant Infant, Newborn Japan/EPIDEMIOLOGY *Maternal-Fetal Exchange Middle Age Pregnancy Prospective Studies Retrospective Studies Seroepidemiologic Methods Support, Non-U.S. Gov't Time Factors JOURNAL ARTICLE


Information in this article was accurate in May 30, 1993. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.